6533b828fe1ef96bd1288597

RESEARCH PRODUCT

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study

Ilaria ScortechiniRiccardo MoiaMarzia VarettoniFrancesca Romana MauroSara GalimbertiGiovanni Del PoetaGraziella D'arrigoMarta CosciaLuca LaurentiErnesto VignaDavide RossiAnnalisa BiagiGianluca GaidanoDaniele CaraccioloRiccardo BombenIlaria AngelettiGianluigi RedaGiovanna CutronaDaniela PietrasantaGilberto FronzaRamona CassinAntonino NeriAaron PolliackAnnalisa ChiarenzaYair HerishanuFortunato MorabitoIlaria Del GiudiceValter GatteiFrancesca RossiRoberta MurruGiovanni TripepiAndrea VisentinLivio TrentinAntonio CuneoAngela RagoAntonella ZucchettoAdalgisa CondoluciGiacomo LosetoUgo ConsoliEnrica Antonia MartinoManlio FerrariniMassimo GentileFrancesco Di RaimondoFrancesco MendicinoPaolo SportolettiRobin FoàCirino Botta

subject

OncologyMalechronic B cell leukemiachronic lymphocytic leukemia; ibrutinib; 4-factor score; prognosis.Datasets as TopicSeverity of Illness Indexchemistry.chemical_compoundPiperidinesRetrospective analysisMulticenter Studies as TopicChronicLeukemiaHematologyMiddle AgedPrognosisLymphocyticProgression-Free SurvivalIbrutinibFemalemedicine.medical_specialtyreal-word studyFactor scoreAntineoplastic AgentsAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Severity of Illness Index; Survival AnalysisRisk AssessmentNOibrutinibInternal medicineSeverity of illnessmedicineHumansProgression-free survivalProtein Kinase InhibitorsSurvival analysisAgedProportional Hazards ModelsRetrospective Studiesbusiness.industryProportional hazards modelAdenineB-CellReproducibility of ResultsRetrospective cohort studyAdenine; Aged; Antineoplastic Agents; Datasets as Topic; Female; Follow-Up Studies; Humans; Leukemia Lymphocytic Chronic B-Cell; Male; Middle Aged; Multicenter Studies as Topic; Piperidines; Prognosis; Progression-Free Survival; Proportional Hazards Models; Protein Kinase Inhibitors; Reproducibility of Results; Retrospective Studies; Risk Assessment; Survival Analysis; Severity of Illness IndexLeukemia Lymphocytic Chronic B-CellSurvival AnalysisSettore MED/15 - MALATTIE DEL SANGUEchemistrybusinesschronic lymphocytic leukaemiaFollow-Up Studies

description

Not Available

yearjournalcountryeditionlanguage
2021-01-01
10.1002/ajh.26127http://hdl.handle.net/2318/1801336